Genetic inactivation of Smo in a mouse model of CML decreases the number of CML LSCs, whereas constitutively-active Smo results in a four-fold increase in CML LSCs, leading to accelerated CML tumourigenesis [104]. The gene discussed is SMO; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.